Hengrui Medicine: Ruiruamabine tablets approved for Phase III clinical trials of prostate cancer

Hengrui Pharmaceuticals announced that it has recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Ruramine Tablets, and will soon carry out clinical trials. The approval conclusion states that the drug is approved to conduct Phase III clinical trials for prostate cancer. Ruramine Tablet is a second-generation AR inhibitor that was approved for marketing in 2022. Similar products had a global sales revenue of approximately $11.037 billion in 2024, with a cumulative research and development investment of approximately 693.09 million yuan in the related projects of this product so far. The drug development and marketing cycle is long and involves many steps, which poses uncertainties.